Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Gross Margin came in at 74.55% in Q1 2026, down 511.0% YoY from 18.14% in Q1 2025, and up 8.87% on a QoQ basis from 68.47% in Q4 2025.
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Gross Margin data on file, last reported at 74.55% in Q1 2026.
- Quarterly Gross Margin fell 511.0% year-over-year to 74.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.53% (down 291.0% YoY) and the FY2025 annual result came in at 77.73%, down 194.0% from the prior year.
- Gross Margin rose to 74.55% in Q1 2026, from 68.47% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 81.95% in Q3 2025 to a low of 68.47% in Q4 2025.
- A 5-year average of 77.73% and a median of 77.97% in 2023 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 722 bps in 2025, down 1331 bps in 2025.
- Tracing BMRN's Gross Margin over 5 years: stood at 72.72% in 2022, then rose by 8 bps to 78.66% in 2023, then increased by 4 bps to 81.78% in 2024, then fell by 16 bps to 68.47% in 2025, then grew by 9 bps to 74.55% in 2026.
- The last three Gross Margin figures came in at 74.55% (Q1 2026), 68.47% (Q4 2025), and 81.95% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | 79.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.51% |
| Mar 31, 2026 | 74.55% |
| Dec 31, 2025 | 68.47% |
| Sep 30, 2025 | 81.95% |
| Jun 30, 2025 | 81.82% |
| Mar 31, 2025 | 79.66% |
| Dec 31, 2024 | 81.78% |
| Sep 30, 2024 | 74.73% |
| Jun 30, 2024 | 81.68% |
| Mar 31, 2024 | 80.71% |
| Dec 31, 2023 | 78.66% |
| Sep 30, 2023 | 77.97% |
| Jun 30, 2023 | 78.06% |
| Mar 31, 2023 | 77.29% |
| Dec 31, 2022 | 72.72% |
| Sep 30, 2022 | 76.99% |
| Jun 30, 2022 | 76.93% |
| Mar 31, 2022 | 77.48% |
| Dec 31, 2021 | 73.38% |
| Sep 30, 2021 | 74.67% |